Today: 2 February 2026
Subscribe
Browse Category

Biotechnology News 8 October 2025 - 15 October 2025

Sana Biotech Shares Skyrocket on 100x Hype – What’s Behind the Rally?

Sana Biotech Shares Skyrocket on 100x Hype – What’s Behind the Rally?

Stock Surge Fueled by ‘100-Bagger’ Tweet On Oct. 15, SANA spiked as investors reacted to hedge fund manager Eric Jackson’s bullish call. In a post on X (formerly Twitter), Jackson proclaimed: “Biotech is back. Rates are falling, inflation is cooling, and money is rotating from megacaps to growth again,” and suggested “$SANA looks like the next 100-Bagger platform” Benzinga. Benzinga…
15 October 2025
····
Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Volatile Stock Performance in October 2025 Recursion’s stock showed wild swings in early October. On Oct 7, 2025 the shares fell about 5.4% to ~$5.23 amid a broad market slump Nasdaq. The very next day (Oct 8) the stock rebounded sharply, jumping roughly 16% to ~$6.08 ts2.tech. This put RXRX near the middle of its 52-week trading range (about $3.97–$10.87)…
15 October 2025
····
Origin Agritech’s SEED Stock Skyrockets 92% on China Seed Breakthroughs & Trade Buzz

Origin Agritech’s SEED Stock Skyrockets 92% on China Seed Breakthroughs & Trade Buzz

SEED Stock Soars on Market Momentum Origin Agritech’s stock skyrocketed this week, delivering eye-popping gains for investors. On Tuesday night, SEED shares surged over 92% in after-hours trading following a flurry of positive developments Benzinga. The price spiked from the $1.40 range to roughly $2.76 in extended trading – nearly a doubling overnight. By Wednesday Oct. 15, the stock opened…
15 October 2025
·
Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough

Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough

Evaxion’s stock jump in mid-October comes as the company lines up important clinical updates and validates its AI-driven vaccine technology. On Oct 13, Evaxion announced it will present two-year data from its Phase 2 trial of EVX-01 (a personalized cancer vaccine for advanced melanoma) at the ESMO Congress in Berlin Globenewswire. The October presentation (oral session Oct 17, webinar Oct 22) will cover…
15 October 2025
···
Arcadia Biosciences Stock Rockets Amid Trade News – What’s Behind RKDA’s Wild Ride?

Arcadia Biosciences Stock Rockets Amid Trade News – What’s Behind RKDA’s Wild Ride?

In-Depth: Arcadia’s stock price (RKDA) has been extremely volatile in October 2025, jumping ~68% pre-market on Oct 15. The rally was sparked by a Trump tweet on China trade and follows mixed Q2 results. In the past few days RKDA’s trading range has widened dramatically. After closing at $3.69 on Oct 14 Stockanalysis, pre-market Oct 15 it was near $6.22…
15 October 2025
····
Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Stock Price & Recent Performance Genprex shares have been extremely volatile. After surging over 30% during regular hours on Oct 14, 2025, to about $0.25, the stock jumped another 41% in after-hours trading (October 14) to roughly $0.36 on the cancer data announcement Benzinga Benzinga. That rally brought the stock briefly near its 30-day resistance around $0.26 Ainvest. Before this…
15 October 2025
··
Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Background and Pipeline Intellia was an early pioneer of in-vivo CRISPR therapy. Based in Cambridge, MA, it was among the first to administer CRISPR-Cas9 therapies directly into patients ts2.tech. In 2021 Intellia reported the first clinical proof that in-body CRISPR editing could work – a single injection dramatically lowered the disease protein (transthyretin) in ATTR amyloidosis patients ts2.tech. Today,…
9 October 2025
···
AI Drug Discovery Goldmine? Inside Recursion Pharma’s Wild Stock Surge and What’s Next

AI Drug Discovery Goldmine? Inside Recursion Pharma’s Wild Stock Surge and What’s Next

Latest News (Oct 7–Oct 9, 2025) Stock Performance & Technical Analysis After languishing through the summer, Recursion’s share price came to life in early October 2025. By Oct 8 the stock had rebounded to around $6.09 Insidermonkey, putting it near the middle of its volatile 52-week range ($3.97 – $10.87) ts2.tech. For context, RXRX had traded in the double-digits when…
9 October 2025
···
Xenetic Biosciences (XBIO) Stock Skyrockets – Is the Biotech’s 2025 Rally for Real?

Xenetic Biosciences (XBIO) Stock Skyrockets – Is the Biotech’s 2025 Rally for Real?

Stock Performance: The 2025 Rollercoaster Ride Xenetic’s stock was relatively quiet for most of 2025 until early October, when it suddenly erupted. By Oct 8, 2025, XBIO had skyrocketed to levels not seen in years. On that day alone, the stock soared 123% to $9.58 (from a prior $4.29 close) Finanzen, after touching intraday highs well above $10. This move extended a remarkable…
8 October 2025
··
Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Detailed Report 1. Stock Performance and Valuation Moderna’s stock was a market darling during the pandemic but has suffered a long decline. On Oct 7 2025 (the last trading day before the U.S. Columbus Day holiday), the stock closed at $27.34, down roughly 0.7% from $27.54 on the prior session Stockinvest. Technical analysts at Stockinvest.us noted the shares were near the upper…
8 October 2025
····
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects

Quick Facts (as of 8 Oct 2025) Recent Performance and News Phase 1 data fuels rally Intellia’s October rally was triggered by longer‑term Phase 1 results for nexiguran ziclumeran (nex‑z), an in‑vivo CRISPR therapy for transthyretin (ATTR) amyloidosis. A GlobeNewswire release (Sept 25 2025) reported that a single dose produced a rapid, deep and durable reduction of serum TTR levels—mean reduction 92 % at 24 months and 90 %…
8 October 2025
···
CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

Stock Price, Volume and Sentiment According to AAII, CRSP’s share price on 8 Oct 2025 closed at $77.727, up 10.06 % from the previous close. The stock traded between $70.77 and $78.38 that day and has risen ~20 % during October. Over the prior year the share price ranged from $30.04 to $73.95, and year‑to‑date performance stood at +97.5 %. Trading volume on INDmoney’s quote…
8 October 2025
···
1 … 20 21 22 23 24

Stock Market Today

  • Nifty 50 and Sensex Start Mixed Amid Budget Impact; Hero Moto, Hyundai, UPL in Focus
    February 2, 2026, 8:44 AM EST. India's stock benchmarks showed mixed movements Monday after sharp losses on budget day. The Nifty 50 opened slightly down 0.12% at 24,796.5, and the Sensex slipped 0.21% to 80,555.68 as investors reacted to federal budget measures, including a higher Securities Transactions Tax (STT) on derivatives. Markets bounced back later, with the Nifty 50 climbing 1.06% to 25,088.4 by mid-afternoon, and the Sensex up 1.17% to 81,666.46. Infrastructure stocks and Reliance Industries led gains. Several companies, including Hyundai Motor India, UPL, and Bajaj Housing Finance, are set to announce Q3 results, potentially impacting market direction. Asian markets traded mixed, while the US stocks ended lower last week.
Go toTop